Quick Facts

• May be used in the management of chickenpox (varicella).
• An option for the acute treatment of shingles (herpes zoster).
• Considered for the treatment and management of initial and recurrent genital herpes episodes.
• Used in the context of certain herpes simplex virus (HSV) infections.

---

Aciclovir is an antiviral medication used to address infections caused by the herpes virus family, including herpes simplex virus (HSV) and varicella-zoster virus (VZV). The primary therapeutic use of this agent is the management of VZV infections, which cause both chickenpox (varicella) and shingles (herpes zoster). Timely administration may help to support the healing process of related sores and blisters and may contribute to managing associated discomfort.

The medication is also utilized in treating initial episodes of genital herpes and for the chronic management of recurrent outbreaks. It is considered for the treatment of certain herpes simplex infections affecting the skin and mucous membranes. While Aciclovir helps relieve symptoms and supports healing, it does not offer a cure for these viral infections or prevent the transmission of the virus to other individuals. Healthcare providers should determine the appropriate use based on the specific infection.

---

Regulatory References

1. NIH MedlinePlus guidance

Aciclovir's eligibility profile is defined by specific population rules established in official regulatory labeling. Use is strictly contraindicated in patients with a demonstrated hypersensitivity reaction (allergy) to aciclovir, to its pro-drug valaciclovir, or to any of the specific excipients present in the formulation.

---

Conditional Use and Restrictions

Population Group	Regulatory Status and Constraint
Renal Impairment	Restricted use requiring mandatory dose adjustment based on the degree of reduced kidney function, as the drug is primarily eliminated by the kidneys.
Older Adults (Geriatric)	Use requires special caution; dose reduction may be necessary due to age-related decline in renal function, even if not overtly impaired.
Pregnancy/Lactation	Use is restricted and considered only when the potential clinical benefit is judged to outweigh the potential risks. Caution is advised during breastfeeding as the drug passes into breast milk.
Dehydration	Use requires caution; patients must maintain adequate hydration to help prevent the risk of acute kidney injury, particularly with intravenous administration.

---

Most adults and children are eligible for treatment, though eligibility for specific pediatric groups (e.g., infants) and for topical formulations is indication- and age-dependent. Caution is also advised for patients with pre-existing neurological conditions.

The official regulatory profile for Aciclovir interactions is primarily defined by the drug's elimination pathway via active renal tubular secretion.

Interaction Scope

Specific interacting medicinal products include Probenecid, Cimetidine, and Mycophenolate Mofetil. These substances share the same renal clearance mechanism, resulting in a pharmacokinetic interaction where co-administration officially reduces Aciclovir renal clearance and increases its plasma concentrations and Area Under the Concentration-time Curve (AUC). Aciclovir also affects Theophylline levels, officially increasing its AUC by approximately 50%.

A distinct pharmacodynamic risk is documented with Other Nephrotoxic Drugs, as co-use increases the risk of renal dysfunction. Co-administration with Zidovudine is officially associated with fatigue. The FDA label confirms that food has no effect on Aciclovir absorption.

Interaction Classifications (High-Level)

The regulatory basis for this profile stems from official FDA and EMA documentation, defining the key interactions as Use with Caution due to altered drug exposure or additive toxicity risk. Geriatric patients and those with renal impairment represent specific populations where age-related or compromised renal function can lead to higher Aciclovir plasma concentrations, potentially amplifying these interaction effects. No mandatory timing separation rules are documented in the labeling.

Selective Activation by Viral Enzymes

The mechanism begins with Aciclovir acting as a prodrug that requires activation almost exclusively within virus-infected cells. This activation relies on the viral enzyme thymidine kinase (TK), which is preferentially expressed only when the virus is actively replicating. Viral TK performs the initial phosphorylation step, converting Aciclovir into its active intermediate form. Subsequent host kinase activity converts this intermediate to the active metabolite, Aciclovir triphosphate (ACV-TP), resulting in the preferential accumulation of the active metabolite in virus-infected cells.

Irreversible Genomic Chain Termination

Once formed, ACV-TP directly targets the viral DNA polymerase. It acts as a competitive inhibitor and is mistakenly incorporated into the growing viral DNA chain. Because the incorporated drug lacks a critical chemical structure, it instantly halts further elongation, resulting in DNA chain termination. This simultaneous inhibition and physical disruption lead to the irreversible inactivation of the enzyme, completely shutting down the viral DNA synthesis pathway.

Blockade of Viral Proliferation

The complete cessation of viral DNA synthesis prevents the virus from generating new genetic material and fully mature progeny particles. This molecular blockade translates to a restriction on the ability of the virus to spread from one cell to the next, thereby limiting the overall acute viral burden in the affected tissue. This physiological consequence restricts the dissemination of the virus.

Official Administration Guidelines

Aciclovir is administered through multiple official routes, which determine its usage pattern. These include oral forms (tablets, capsules, and suspension) for systemic effect, intravenous (IV) for severe infections, and topical (cream, ointment), ophthalmic, or buccal (adhesive tablet) for localized application. The medicine should be taken at the earliest sign or symptom of the condition.

Dosing and Scheduling

Dosing regimens are highly specific to the context of use, with oral doses typically ranging from 200 mg to 800 mg per unit dose. Oral forms are generally scheduled four or five times daily for acute treatment, or twice daily for long-term suppressive use. Treatment duration ranges from short courses (5 to 10 days) to continuous administration for up to twelve months. Oral forms may be taken with or without food; however, patients must drink plenty of water with each dose to facilitate renal clearance.

Special Procedural Conditions

For intravenous administration, the lyophilized powder requires reconstitution and subsequent dilution before infusion and must be administered slowly over a minimum of one hour. The buccal tablet is applied as a single dose to the upper gum and must not be crushed, chewed, sucked, or swallowed. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next dose, in which case the missed dose must be skipped.

Population-Specific Rules

Dosage adjustment is mandatory for all routes in patients with reduced renal function, where the dose and frequency must be calculated based on the patient’s measured creatinine clearance. Dose reduction may also be necessary for older adults due to the increased probability of age-related changes in renal function.

Recent Clinical Evidence: Aciclovir

The efficacy of Aciclovir is supported by a large body of clinical research, primarily focusing on infections caused by the Herpes Simplex Virus (HSV) and the Varicella-Zoster Virus (VZV), which are responsible for conditions like genital herpes, cold sores, chickenpox, and shingles.

---

Findings in Herpes Zoster (Shingles)

• Accelerated Resolution: Multiple randomized controlled trials and subsequent meta-analyses indicate that oral Aciclovir, when initiated promptly (ideally within 48 to 72 hours of rash onset), accelerates the resolution of zoster-associated pain compared to placebo. This benefit is often most evident in patients aged 50 and older.
• Postherpetic Neuralgia (PHN): Research has evaluated whether Aciclovir is associated with a lower prevalence of persistent pain known as PHN at 3 and 6 months post-rash. While treatment has shown a positive influence on the time to complete pain cessation, the effect on preventing PHN is less certain.

---

Findings in Herpes Simplex Virus

• Genital Herpes: Clinical studies have demonstrated that Aciclovir therapy for initial outbreaks of genital herpes is associated with decreased duration of viral shedding and pain. Suppressive therapy, typically used for frequent recurrences, has been found to reduce the frequency of future outbreaks by approximately 70% to 80%.
• Topical vs. Systemic: While systemic (oral or intravenous) administration is generally effective, the clinical benefit of topical Aciclovir creams for recurrent cold sores is modest, typically reducing the healing time by about one to two days compared to placebo.

---

Safety and Special Populations

Aciclovir is generally considered well-tolerated. However, because the compound is primarily excreted by the kidneys, clinical management requires careful dose adjustment in patients with impaired renal function to mitigate the risk of adverse events, including possible kidney injury and neurologic changes.

Key Studies & References

1. Oral antiviral therapy for the treatment of herpes zoster
2. Aciclovir: Drug Information (Pharmacokinetics and Renal Dosing)

Common questions about Aciclovir (FAQ)

---

Q: What is the main difference between Aciclovir cream and tablets?

According to official administration guidelines, Aciclovir tablets and capsules are designed to provide a systemic effect, meaning the medicine works throughout your body. In contrast, Aciclovir cream and ointment formulations are for topical, localized application directly on the affected area.

---

Q: Does Aciclovir cure the virus, or just treat the symptoms?

Aciclovir is described in regulatory documents as an inhibitor that works to control the virus's ability to replicate itself. While it helps to limit the overall severity and reduce the duration of the infection, it does not fully eliminate the virus from the body.

---

Q: How quickly does Aciclovir start working after I take it?

Official pharmacological information indicates that for the oral forms, the medication reaches its peak plasma concentration (its highest level in the blood) typically between 1.5 and 2 hours after being taken. This measurement indicates when the drug is most available to the body to begin its effect.

---

Q: Is Aciclovir the same as Zovirax?

Zovirax is a well-known brand name for the drug. According to the prescribing information, the active ingredient in Zovirax is, in fact, Aciclovir (sometimes called Acyclovir). This means they contain the identical therapeutic compound.

---

Q: What happens if I stop taking Aciclovir early?

Regulatory documents emphasize the value of completing the full prescribed course. Following the full course helps support the treatment's objective of acute infection resolution and minimizes the risk of reduced viral susceptibility.

---

Q: Does Aciclovir cause sun sensitivity?

Yes, official product information includes a warning that Aciclovir can make the skin more sensitive to the sun. Due to this effect, labeling indicates patients should protect themselves from sun exposure while using the medication.

---

Q: Are there any known issues with drinking alcohol while using Aciclovir?

Official labeling does not contain a direct prohibition against alcohol consumption. However, Aciclovir can cause side effects like dizziness. Official information suggests using caution, especially since alcohol may potentially increase these types of effects.

---

Q: Can children use Aciclovir, and is the dosage different?

Yes, Aciclovir is officially indicated for use in children. Regulatory dosing and administration sections emphasize that the necessary dosage is highly specific and must be determined based on the child's age, weight, and the specific infection being treated.

---

Q: Why is Aciclovir sometimes called Acyclovir in other countries?

This is simply due to international naming conventions. Acyclovir is the common name used in the United States and is officially referred to as the US Adopted Name (USAN). Aciclovir is the name used internationally.

---

Q: What are the official uses for Aciclovir eye ointment?

The official product information for the ophthalmic formulation specifies its indication. Aciclovir eye ointment is used for the treatment of acute herpetic keratitis, which is an infection of the eye caused by the herpes simplex virus.

---

Q: Is Aciclovir useful for all types of viral infections?

No. Official regulatory documents describe Aciclovir as a selective inhibitor that is primarily active against certain viruses. Its main uses are targeted at infections caused by the Herpes family of viruses, such as Herpes Simplex (HSV) and Varicella-Zoster (VZV).

---

Q: Is it true that resistance to Aciclovir can develop?

Yes, the official virology information notes that resistance to the drug can develop. This typically results from genetic changes in the viral enzymes, and reduced susceptibility has been observed, particularly in certain immunocompromised patients.

---

Q: Are there different strengths of Aciclovir cream?

Regulatory documents detailing the 'how supplied' information indicate that Aciclovir cream and ointment are typically supplied as a 5% formulation for topical use.

---

Q: Do studies suggest Aciclovir is effective for eye infections caused by the herpes virus?

Yes. The indication of the ophthalmic formulation itself confirms the evidence, as it is officially approved for treating acute herpetic keratitis, an eye infection caused by the herpes virus.

---

Q: Is there any difference in effectiveness between brand-name and generic Aciclovir?

Regulatory guidance requires that generic Aciclovir products must be bioequivalent to the brand-name product. This means the generic version must contain the identical active ingredient, be of the same strength and form, and work in the body in the same way.

---

Q: Can I use Aciclovir cream on other skin conditions, not just cold sores?

Official product labeling indicates that Aciclovir cream is strictly approved only for the treatment of Herpes Simplex Virus infections, such as cold sores. It is not indicated or approved for use on other, non-viral skin conditions.

---

Q: Are there any long-term health risks associated with taking Aciclovir?

The safety profile indicates that most serious adverse events, such as acute renal failure, are associated with factors like inadequate hydration during use or underlying patient conditions. The less frequent side effects are generally reversible when the drug is stopped.

---

Q: How is Aciclovir different from Valaciclovir?

The official documentation mentions that Valaciclovir is the pro-drug of Aciclovir. This means Valaciclovir is converted into Aciclovir once it is absorbed by the body. This structural difference means Valaciclovir may have different absorption characteristics in the body.

---

Q: Can Aciclovir cause changes in mood or behavior?

The safety profile lists possible neurological reactions, particularly in older adults and patients with kidney issues. These adverse events are described as severe but generally reversible and can manifest as alterations in mental state.

Aciclovir oral formulations must be stored at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F), with some products permitting excursions up to 30 C. The medicine must be kept in a tight, light-resistant container and be protected from moisture. Specific liquid formulations must not be frozen or refrigerated, as this can cause crystallization.

Storage Requirements

Storage Condition	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Protection	Protect from moisture and light
Child Safety	Keep out of the sight and reach of children

Disposal Instructions

Unused or expired aciclovir must be disposed of in accordance with local requirements. For environmental protection, regulatory labels for some formulations explicitly advise not to throw the medicine away via wastewater or household waste. Patients should follow local guidelines or use an approved drug take-back program for proper disposal.